Загрузка...
Activation of CD8(+) T cells contributes to antitumor effects of CDK4/6 inhibitors plus MEK inhibitors
Concurrent MEK and CDK4/6 inhibition shows promise in clinical trials for patients with advanced-stage mutant BRAF/NRAS solid tumors. The effects of CDK4/6 inhibitor (CDK4/6i) in combination with BRAF/MEK targeting agents on the tumor immune microenvironment are unclear, especially in melanoma for w...
Сохранить в:
| Опубликовано в: : | Cancer Immunol Res |
|---|---|
| Главные авторы: | , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7484433/ https://ncbi.nlm.nih.gov/pubmed/32661093 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-19-0743 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|